Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing's sarcoma

European Journal of Cancer

Volumn 42, Issue 12, 2006, Pages 1904-1911

  Kreuter, Michael ^a   Paulussen, Michael ^b   Boeckeler, Johannes ^a   Gerss, Joachim ^a   Buerger, Horst ^c   Liebscher, Caren ^a   Kessler, Torsten ^a   Jurgens, Heribert ^b   Berdel, Wolfgang E ^a   Mesters, Rolf M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Angiogenesis; Ewing's Sarcoma; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY; DISEASE FREE SURVIVAL; EWING SARCOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYSTEMIC THERAPY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; REGRESSION ANALYSIS; SARCOMA, EWING'S; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33746590349     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.063     Document Type: Article

References (30)

1. Folkman J., Watson K., Ingber D., and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 (1989) 58-61
2. Hasan J., Byers R., and Jayson G.C. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86 (2002) 1566-1577
3. Hicklin D.J., and Ellis L.M. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
4. Paulusssen M., Frohlich B., and Jurgens H. Ewing tumor: incidence, prognosis and treatment options. Paediatr Drugs 3 (2001) 899-913
5. Cotteril S.J., Ahrens S., Paulussen M., et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 18 (2000) 3108-3114
6. Paulussen M., Ahrens S., Dunst J., et al. Localized Ewing tumor of bone: final results of the Cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 19 (2001) 1818-1829
7. Yudoh K., Kanamori M., Ohmori K., Yasuda T., Aoki M., and Kimura T. Concentration of vascular endothelial growth factor in the tumor tissue as a prognostic factor of soft tissue sarcomas. Brit J Cancer 84 (2001) 1610-1615
8. Chao C., Al-Saleem T., Brooks J.J., Rogatko A., Kraybill W.G., and Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 8 (2001) 260-267
9. Fuchs B., Inwards C.Y., and Janknecht R. Vascular Endothelial Growth Factor is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 10 (2004) 1344-1353
10. Simpson A., Gimer R., Mangham C., Cullinane C., Lewis I., and Burchill S.A. MVD predicts disease free and overall survival in tumours of the Ewing's sarcoma family (EFST). Brit J Cancer 86 Suppl. 1 (2002) S95
11. Dalal S., Berry A.M., Cullinane C.J., et al. Vascular Endothelial Growth Factor: therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 11 (2005) 2364-2378
12. Kreuter M., Bieker R., Bielack S.S., et al. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res 10 (2004) 8531-8537
13. Jürgens H., Exner U., Gadner H., et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61 (1988) 23-32
14. Paulussen M., Craft A.W., and Ian Lewis I. Ewing tumor of bone - updated report of the European Intergroup Cooperative Ewing's Sarcoma Study EICESS 92. ProcASCO 21 (2002) 393 Abstr. 1568
15. Salzer-Kuntschik M., Brand G., and Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe 4 (1983) 135-141
16. Enneking W.F., Spanier S.S., and Goodmann M.A. A system for the surgical staging of muscolo-skeletal tumors. Clin Orthop 153 (1980) 106-120
17. Padro T., Bieker R., Ruiz S., et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16 (2002) 1302-1310
18. Lewis I., Burchill S., and Souhami R. Ewing's sarcoma and the Ewing family of tumours. In: Souhami R.L., Tannock I., Hohenberger P., and Horiot J.C. (Eds). Oxford textbook of oncology (2002), Oxford University Press, Oxford 2539-2551
19. Vermeulen P.B., Gasparini G., Fox S.B., et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32 (1996) 2474-2484
20. Zhou Z., Zhou R.R., Guan H., Bucana C.D., and Kleinerman E.S. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Mol Cancer Ther 2 (2003) 1313-1319
21. Guan H., Zhou Z., Wang H., Jia S.F., Liu W., and Kleinermann E.S. A small interfering RNA targeting Vascular Endothelial Growth Factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 11 (2005) 2662-2669
22. Tomlinson J., Barsky S.H., Nelson S., et al. Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 5 (1999) 3516-3522
23. 0 esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 8 (2002) 124-130
24. Hoang B.H., Dyke J.P., Koutcher J.A., et al. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res 426 (2004) 32-38
25. Bocci G., Nicolaou K.C., and Kerbel R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62 (2002) 6938-6943
26. Hill S.A., Lonergan S.J., Denekamp J., and Chaplin D.J. Vinca alkaloids, antivascular effects in a murine tumour. Eur J Cancer 29 (1993) 1320-1324
27. Belotti D., Vergani V., Drudis T., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2 (1996) 184318-184349
28. Maragoudakis M.E., Peristeris P., Missirlis E., Aletras A., Andriopoulou P., and Haralabopoulos G. Inhibition of angiogenesis by anthracyclins and titanocene dichloride. Ann NY Acad Sci 732 (1994) 280-293
29. Schirner M., Hoffmann J., Menrad A., and Schneider M.R. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 4 (1995) 1331-1336
30. Sturla L.M., Westwood G., Selby P.J., Lewis I.J., and Burchill S.A. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma. Cancer Res 60 (2000) 6160-6170